BioMarin Finalizes $4.8 Billion Acquisition of Amicus Therapeutics, Secures $3.4 Billion in New Debt

summarizeSummary

BioMarin Pharmaceutical Inc. has completed its previously announced $4.8 billion all-cash acquisition of Amicus Therapeutics, significantly expanding its commercial portfolio with new treatments for rare diseases. The acquisition was financed through a combination of new term loans, previously issued senior notes, and cash on hand.

check_boxKey Events

• Acquisition Completed

  BioMarin finalized its previously announced $4.8 billion all-cash acquisition of Amicus Therapeutics, with Amicus becoming a wholly-owned subsidiary.

• New Product Portfolio

  The acquisition adds commercial treatments Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease), along with the Phase 3 candidate DMX-200 (FSGS), to BioMarin's portfolio.

• Significant Debt Financing

  BioMarin entered into new senior secured credit facilities totaling $3.4 billion, comprising $2.0 billion Term B loans, $800 million Term A loans, and a $600 million revolving credit facility, to fund the acquisition and refinance existing debt.

• Amicus Share Conversion

  Each share of Amicus common stock was converted into the right to receive $14.50 in cash.

auto_awesomeAnalysis

This 8-K filing officially confirms the completion of BioMarin's substantial acquisition of Amicus Therapeutics, a transaction valued at approximately $4.8 billion. This follows the regulatory clearance announced on April 23, 2026. The acquisition is strategically important as it diversifies BioMarin's commercial portfolio by adding two new treatments for lysosomal storage diseases, Galafold and Pombiliti + Opfolda, and a Phase 3 kidney disease candidate, DMX-200. To finance the merger, BioMarin secured new senior secured credit facilities totaling $3.4 billion, including $2.8 billion in funded term loans and a $600 million revolving credit facility, and repaid its existing credit agreement. This significant capital raise and strategic acquisition are expected to impact BioMarin's financial profile and growth trajectory.